NeoImmuneTech Hits Limit-Up for Second Day on U.S. Biotech Deal[K-Bio Pulse]

NeoImmuneTech, a South Korean developer of immuno-oncology drugs, hit its daily upper trading limit Friday for the second consecutive session, following a licensing deal with a U.S. biotechnology com...